Ledipasvir and sofosbuvir Approval Status
- FDA approved: No
- Generic name: ledipasvir and sofosbuvir
- Company: Gilead Sciences, Inc.
- Treatment for: Hepatitis C
Ledipasvir/Sofosbuvir is a once-daily NS5A inhibitor and nucleotide analog polymerase inhibitor fixed-dose combination in development for the treatment of chronic hepatitis C genotype 1 infection.
FDA Approval Status for ledipasvir and sofosbuvir
|Apr 7, 2014||Gilead Announces FDA Priority Review Designation for Ledipasvir/Sofosbuvir Fixed-Dose Combination|
|Feb 10, 2014||Gilead Files for U.S. Approval of Ledipasvir/Sofosbuvir Fixed-Dose Combination Tablet for Genotype 1 Hepatitis C|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.